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Sources searched to identify primary studies
Not relevant.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The review of clinical datasets revealed that, at baseline, the mean BASDAI score was 6.3 (standard deviation, SD=1.4) in the placebo group versus 6.5 (SS=1.1) in the infliximab group. The BASFI scores were 5.1 (SD=2.2) and 5.5 (SD=1.8), respectively. At the end of 12 weeks, the BASDAI score was 5.0 (SD=0.4) in the placebo group versus 3.4 (SD=0.4) in the infliximab group, and the BASFI scores were 5.7 (SD=0.5) and 3.2 (SD=0.4), respectively.
At the end of 54 weeks, the mean BASDAI score and the mean BASFI score reached the same value 2.8 (SD=0.4) for the infliximab group.
The mean duration of duration was 14.9 years (SD=9.3) in the placebo group versus 16.4 years (SD=8.3) in the infliximab group.
The review of the cohort study and the observation survey revealed that the mean BASDAI score was 4.2 (SD=2.3) and the mean BASFI score was 4.4 (SD=2.8).
The mean duration of disease was 30.2 years (SD=11.7).
The article also reported the demographic parameters and the details of these parameters on the basis of five intervals of BASDAI and BASFI scores.
